Clear Trial Podcast: Episode1: Recent Tufts research on assessing clinical trial costs

Dec 01, 2010
By Pharmaceutical Executive

Trends in Assessing Internal and Outsourced Clinical Trial Costs and Resource Demand
Join Reid Paul, Editor in Chief of Pharmaceutical Representative, Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Andy Grygiel, Vice President of Marketing and Product Management at ClearTrial, for Parts 1 and 2 of this podcast series as we discuss recent Tufts research on assessing clinical trial costs and resource demand. In Part 3 of the series, Molly Blake-Michaels, Director, Clinical Services at ClearTrial, examines the pros and cons of the most widely used clinical trial forecasting and budgeting methods in use today by biopharmaceutical and medical device companies.

Episode 1: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Andy Grygiel, Vice President of Marketing and Product Management at ClearTrial, discuss recent Tufts research on assessing clinical trial costs.

Speakers:
Ken Getz
Senior Research Fellow
Tufts Center for the Study of Drug Development

Andy Grygiel
Vice President of Marketing and Product Management
ClearTrial




Add this Podcast feed to your media player

Click Here To Listen to More of the Clear Trial Podcast Series

 
Sponsored By
ClearTrial provides Clinical Trial Operations software that makes the planning, forecasting, and tracking of clinical project and financial performance faster and more accurate.